Because AITL is derived from TFH cells, CXCL13 was first suggested as a biomarker for this disease (70), and the 2016 WHO classification of lymphomas included CXCL13 in the diagnostic criteria for AITL (71). Here, CXCL13 is linked to angioimmunoblastic T-cell lymphoma.